GHRL and neurodegenerative disease: Starting from 2001, four different patents have proposed the use of ghrelin or analogues as preventive/therapeutic agents for neurodegenerative diseases (WO2001047558A1, WO201406534A1, WO2015017123A1, WO2017075535A1).